
TOI Stock Forecast & Price Target
TOI Analyst Ratings
Bulls say
Starling Oncology is positioned as a strong investment opportunity due to their focus on value-based care, adherence to clinical guidelines, and strong growth in their specialty pharmacy segment. Their recent refinancing has improved their liquidity and operating flexibility, allowing them to invest in growth and manage costs effectively. However, competition and potential issues with drug pricing and reimbursement must be monitored. Considering the trading multiples of peer companies, Starling Oncology's stock price is expected to follow a reasonable growth trajectory, with a price target of $8. There are also challenges facing Starling Oncology, such as recruitment and retention of healthcare professionals and potential changes in reimbursement rates, that must be managed to maintain their success in the healthcare industry.
Bears say
Starling Oncology is a community oncology services provider facing intense competition from larger players and independent oncologists. Its growth potential is limited by its geographic footprint and high leverage. With uncertainties around reimbursement pressures and potential for membership declines, the company faces significant risks to its financial performance and ability to scale.
This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.
TOI Analyst Forecast & Price Prediction
Start investing in TOI
Order type
Buy in
Order amount
Est. shares
0 shares